Tecovirimat
Tecovirimat is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.
- Limitation of use:
- Effectiveness of tecovirimat treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical.
- Efficacy may be reduced in immunocompromised patients based on animal models.
- Limitation of use:
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.
- Limitation of use:
- Effectiveness of tecovirimat treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical.
- Efficacy may be reduced in immunocompromised patients based on animal models.
- Limitation of use:
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved